Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2 or AE37 HER2/neu peptide vaccine versus GM-CSF alone for recurrence prevention in high-risk breast cancer
2007-000934-38Phase 2Completed
- Sponsor
- Generex Biotechnology Corporation
- Start
- Jun 2007
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GP2 peptide, AE37 and sargramostim in breast cancer (4 arms), sponsored by Generex Biotechnology Corporation. Primary endpoints: Recurrence prevention and Recurrence rate reduction with GP2. Started Jun 2007; status: completed.
02
Drugs
GP2 peptideAE37sargramostim
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-000934-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000934-38.